The global cholera vaccine market generated $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025.

Cholera is an acute intestinal infection that causes rapidly dehydrating diarrheal disease, which is caused by toxigenic serogroups of the bacterium Vibrio cholera. The disease is closely associated with poverty, poor sanitation and lack of clean drinking water. Historically, devastating outbreaks of cholera resulted in millions of cases and hundreds of thousands of deaths. Currently, cholera remains an important public health problem in many countries, occurring as an endemic disease in some regions and causing major epidemics in some low- and middle-income countries (LMICs). The vaccine is used to control cholera and is mainly recommended for travelers and the people living in cholera-affected region.

There is an increase in the demand for cholera vaccine due to lack of proper sanitation and consumption of contaminated food and growth in the awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players.

The global cholera vaccine market is segmented based on product, end user, and region. Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol and Euvichol-Plus and others. Depending on end user, the market is categorized into hospitals and clinics, research and academic laboratories and others. Based on region, the market is studied across North America, Europe, Asia-Pacific and LAMEA.